Authors
Rodrigo Jover, Thuy–Phuong Nguyen, Lucía Pérez–Carbonell, Pedro Zapater, Artemio Payá, Cristina Alenda, Estefanía Rojas, Joaquín Cubiella, Francesc Balaguer, Juan D Morillas, Juan Clofent, Luis Bujanda, Josep M Reñé, Xavier Bessa, Rosa M Xicola, David Nicolás–Pérez, Antoni Castells, Montserrat Andreu, Xavier Llor, C Richard Boland, Ajay Goel
Publication date
2011/4/1
Journal
Gastroenterology
Volume
140
Issue
4
Pages
1174-1181
Publisher
WB Saunders
Description
BACKGROUND & AIMS
5-Fluorouracil (5-FU)–based adjuvant chemotherapy does not increase survival times of patients with colorectal tumors with microsatellite instability. We determined the response of patients with colorectal tumors with the CpG island methylator phenotype (CIMP) to 5-FU–based therapy.
METHODS
We analyzed a population-based cohort of 302 patients with colorectal cancer (CRC) for a median follow-up time of 50.7 months. CIMP status was determined by analysis of the CACNAG1, SOCS1, RUNX3, NEUROG1, and MLH1 promoters; tumors were considered to be CIMP positive if at least 3 promoters were methylated.
RESULTS
Tumors from 29.5% of patients (89/302) were CIMP positive; CIMP status did not influence disease-free survival (DFS; log-rank = 0.3). Of tumors of TNM stages II–III (n = 196), 32.7% were CIMP positive. Among patients with stages II–III CRC who did not receive …
Total citations
Scholar articles
R Jover, TP Nguyen, L Pérez–Carbonell, P Zapater… - Gastroenterology, 2011